The present invention relates to a stable liquid pharmaceutical formulation comprising 40 mg/ml to 200 mg/ml of an antibody against P-selectin； 0.01% to 0.1% of a poloxamer； 5 mM to 100 mM of a buffer； and 100 mM to 500 mM of at least one stabilizer； at a pH in the range from 4.5 to 7.0.
